Skip to content
Screener

iRadimed IRMD Q1 2026 earnings

Reported May 1, 2026 · Before market open

Revenue$22.0MBeat by $664.0K
EPS$0.49Beat by $0.03
Revenue estimate$21.3M
EPS estimate$0.46

Next report

Nov 2, 2026 (in a month)
Revenue estimate$23.2M
EPS estimate$0.52

Financials

Q1 2026

Income statement

See full
Revenue$22.0M+12.6%
Gross profit$16.8M+13.3%
Operating income$7.2M+33.2%
Net income$5.8M+24.1%
EPS (diluted)$0.45+21.6%

Balance sheet

See full
Cash & equivalents$56.4M+12.0%
Total equity$98.5M+9.4%
Total assets$114.4M+12.4%

Cash flow

See full
Operating cash flow$8.3M+93.2%
CapEx$403.0K-89.1%
Free cash flow$7.9M+1,226%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.23B+84.4%
P/E52.1×+18.4×
P/S14.3×+5.4×

Profitability

See full
Gross margin76.8%-0.1pp
Operating margin32.4%+2.3pp
Net margin27.4%+1.0pp
FCF margin28.4%+8.9pp

Returns & leverage

See full
Return on equity25%+1.2pp
Current ratio7.1×-1.7×

Segments

By product

See full
MRI Compatible IV Infusion Pumps$7.7M+27.8%
MRI Compatible Patient Vital Signs Monitoring Systems$7.1M+8.6%
Disposables$4.9M—
Services and other$1.0M—
Amortization of extended maintenance agreements$659.0K—

FAQ

When did iRadimed report Q1 2026 earnings?
iRadimed (IRMD) reported Q1 2026 earnings on May 1, 2026 before market open.
What were iRadimed's Q1 2026 revenue and EPS?
iRadimed reported revenue of $22.0M and eps of $0.49 for Q1 2026.
Did iRadimed beat estimates in Q1 2026?
Revenue beat the consensus estimate of $21.3M by $664.0K. EPS beat the consensus estimate of $0.46 by $0.03.
How did iRadimed's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.7% from $19.5M a year earlier and eps grew 16.7% from $0.42.
Where can I find iRadimed's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-029125) and the 10-Q periodic report (0001628280-26-029325) directly on SEC EDGAR. The filing index links above go to sec.gov.